Here are the 8-K filings from Zynex Inc (ZYXIQ) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow ZYXIQ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZYXIQ filings page.
Zynex, Inc. has emerged from Chapter 11 protection after a court confirmed reorganization plan became effective on March 26, 2026. As part of the plan, all previously issued equity, including existing common stock and equity awards, was cancelled and extinguished, and 1,000 new common shares were issued to Altivera Medical Holdings LLC, which now owns 100% of the company.
The company entered a new $10.0 million senior secured term loan maturing in 2034, which will convert into common stock once specified payments under a non-prosecution agreement are completed or at maturity. Zynex’s prior $22.3 million DIP facility and $60.0 million convertible notes were discharged. Amended articles now authorize up to 1,000,000 common shares, and new bylaws reset shareholder voting and governance procedures alongside board changes at both the sponsor and company level.
Zynex, Inc. reports that a U.S. bankruptcy court has entered a confirmation order approving its Chapter 11 reorganization plan and disclosure statement. Once conditions are met and the plan becomes effective, all existing equity interests, including the current 30,781,021 common shares, will be cancelled, released and extinguished. Approximately 1,000 new common shares will be issued to an entity owned by the DIP lenders as the plan sponsor, alongside $10 million of takeback debt. The company cautions that trading in its securities is highly speculative and expects existing equity holders to experience a significant loss on their investment if the restructuring transactions are implemented.
Zynex, Inc. reported that the U.S. Securities and Exchange Commission has concluded its investigation and, based on information available, does not intend to recommend an enforcement action against the company. This investigation had been previously disclosed.
The company also reminds investors that its common stock was delisted from Nasdaq following the commencement of voluntary Chapter 11 cases and now trades on the Pink Limited Market under the symbol ZYXIQ. Zynex cautions that trading in its securities during the Chapter 11 process is highly speculative, as the restructuring is expected to cause equity holders to experience a significant loss and the common stock is likely to be cancelled.
Zynex, Inc. entered into a non-prosecution agreement with the U.S. Attorney’s Office for the District of Rhode Island covering past conduct primarily from 2017 to August 2025 under prior management. The company admitted responsibility for acts described in the agreement and related statement of facts.
Under the agreement, Zynex will pay a criminal monetary penalty between $5 million and $12.5 million, depending on earnings and profit through the term, and will forfeit about $85 million in TRICARE billings and about $13 million in other payor billings via release of unpaid claims. Obligations run until the penalty is fully paid or December 31, 2034, whichever is later, and effectiveness is subject to approval by the U.S. Bankruptcy Court in the company’s ongoing Chapter 11 cases.
The company highlights enhanced compliance and governance reforms and ongoing cooperation commitments to authorities. Zynex is in Chapter 11 in the Southern District of Texas, its stock has been delisted from Nasdaq and now trades on the Pink Limited Market under “ZYXIQ,” and it warns that equity holders are expected to experience a significant loss on their investment if its restructuring transactions are implemented.
Zynex, Inc. describes its ongoing Chapter 11 restructuring and recent delisting from Nasdaq. The company and certain subsidiaries have been in voluntary Chapter 11 cases in the Southern District of Texas since December 15, 2025, with the cases jointly administered under a single caption.
On February 7, 2026, Zynex filed a Third Amended Combined Disclosure Statement and Joint Plan of Reorganization, and began soliciting votes on February 9, 2026, with a voting deadline of March 12, 2026. The plan follows a restructuring support agreement and incorporates a global settlement among the company parties, an ad hoc noteholder group and the official committee of unsecured creditors. It contemplates an equity transaction with a plan sponsor selected through a sale process and distribution of any excess sale proceeds under the plan.
Nazdaq determined to delist Zynex’s common stock following the Chapter 11 filings, and the shares were suspended and moved to trade on the Pink Limited Market under the symbol ZYXIQ. Zynex cautions that trading in its securities is highly speculative, states it expects equity holders to experience a significant loss on their investment, and notes the likelihood of cancellation of its common stock in the Chapter 11 process.
Zynex, Inc. provides an update on its ongoing chapter 11 restructuring and related stock exchange status. The company and certain subsidiaries have been operating under voluntary chapter 11 cases in the U.S. Bankruptcy Court for the Southern District of Texas since December 15, 2025.
Zynex has filed a Second Amended Combined Disclosure Statement and Joint Plan of Reorganization that remains consistent with its Restructuring Support Agreement and contemplates an equity transaction with a plan sponsor selected through a sale process. The plan incorporates a Global Settlement among the company parties, an ad hoc noteholder group and the official committee of unsecured creditors.
The plan also establishes a trust for holders of allowed convertible notes claims and general unsecured claims, funded on the plan’s effective date with $750,000 of initial funding, D&O insurance policies and certain estate claims and causes of action. Separately, Zynex notes that its common stock has been delisted from Nasdaq following the chapter 11 filings and now trades on the Pink Limited Market under the symbol ZYXIQ, with deregistration under Section 12(b) to follow effectiveness of Nasdaq’s Form 25. The company cautions that trading in its securities is highly speculative and expects equity holders to experience a significant loss if the restructuring transactions are implemented.